Panzinorm 10000,21 pcs.

Panzinorm 10000 is a combined drug, the effect of which is due to the components included in its composition. The drug compensates for the insufficiency of the external secretory function of the pancreas.

The high lipase activity plays an important role in the treatment of maldigestion due to pancreatic enzyme insufficiency.

Lipase breaks down fats by hydrolysis into fatty acids and glycerol, thus promoting their absorption and the absorption of fat-soluble vitamins.

Amylase breaks down carbohydrates into dextrins and sugars, while protease breaks down proteins.

The drug has a protective coating so that the active enzymes are released in the small intestine, where the pancreatic enzymes act.

The enzymes in pancreatin include lipase, amylase and protease, which facilitate the digestion of fats, carbohydrates and proteins and thus contribute to their more complete absorption in the small intestine. It alleviates symptoms resulting from digestive disorders (a feeling of heaviness and overflow of the stomach, flatulence, shortness of breath, shortness of breath due to accumulation of gas in the intestines, and diarrhea).

It improves digestion in children; stimulates the release of their own pancreatic, stomach and small intestinal enzymes and bile.

Pharmacokinetics

Panzinorm 10000 comes in the form of a capsule, inside which there are pellets covered by a film coating. The film coating of the pellets protects the active enzymes from the acidic environment of the stomach, allowing the enzymes to be released in the small intestine. Most of the enzymes are inactivated, through autolysis and proteolysis. A small portion of the digestive enzymes is excreted through the intestine.

Indications

feeling of fullness in the stomach when overeating, eating fatty or unusual foods
chronic pancreatitis
replacement therapy for pancreatic insufficiency
preparation for examinations of the abdominal organs.

Pharmacological effect

Panzinorm 10000 is a combination drug, the effect of which is determined by the components included in its composition. The drug compensates for the insufficiency of the exocrine function of the pancreas.

High lipase activity plays an important role in the treatment of maldigestion caused by pancreatic enzyme deficiency.

Lipase breaks down fats by hydrolysis into fatty acids and glycerol, thus promoting their absorption and the absorption of fat-soluble vitamins.

Amylase breaks down carbohydrates into dextrins and sugars, while protease breaks down proteins.

The drug has a protective shell, thanks to which active enzymes are released in the small intestine, where pancreatic enzymes act.

The enzymes lipase, amylase and protease included in pancreatin facilitate the digestion of fats, carbohydrates and proteins, which contributes to their more complete absorption in the small intestine. Eliminates symptoms resulting from digestive disorders (a feeling of heaviness and fullness in the stomach, flatulence, a feeling of lack of air, shortness of breath due to the accumulation of gases in the intestines, diarrhea).

Improves the process of digestion of food in children; stimulates the secretion of its own enzymes of the pancreas, stomach and small intestine, as well as bile.

Pharmacokinetics

Panzinorm 10000 is produced in the form of a capsule, which contains pellets covered with a film shell. The film coating of the pellets protects active enzymes from the acidic environment of the stomach, which allows the enzymes to be released in the small intestine. Most enzymes are inactivated as a result of autolysis and proteolysis. A small part of digestive enzymes is secreted through the intestines.

Special instructions

Panzinorm 10,000 should be taken without chewing, with sufficient liquid.

In cystic fibrosis, if the required dose of pancreatin is exceeded (more than 10,000 EUR F lipase units per 1 kg of body weight), strictures (fibrous colonopathy) may develop in the ileocecal region and in the ascending colon. Therefore, for cystic fibrosis, the dose should be adequate to the amount of enzymes that is necessary for the absorption of fats, taking into account the quality and quantity of food consumed.

If symptoms of intestinal obstruction appear while taking Panzinorm 10,000 capsules, fibrous colonopathy should be excluded.

With long-term use, iron supplements are prescribed simultaneously.

Impact on the ability to drive a car and other mechanical means: there is no evidence of a negative effect on the ability to drive a car or operate other mechanisms.

Active ingredient

Pancreatin

Composition

Active ingredient:

pancreatin powder (pork, in pellet form) 96.6–123.9 mg;

Excipients:

gelatin;

titanium dioxide (E171);

sodium lauryl sulfate.

Pregnancy

The use of Panzinorm 10,000 during pregnancy and lactation (breastfeeding) is possible only if the expected positive effect of therapy outweighs the possible risk, due to the lack of clinical data confirming the safety of the use of pancreatic enzymes in this category of patients.

Contraindicated for children under 3 years of age.

Contraindications

Acute pancreatitis
hypersensitivity to the components of the drug Panzinorm 10000.

Side Effects

Allergic reactions: hypersensitivity reactions, incl. skin hyperemia, skin rash, itching; airway obstruction.

From the digestive system (when taking large doses of the drug), nausea, vomiting, abdominal pain (including intestinal colic), diarrhea, constipation, perianal irritation, irritation of the oral mucosa.

In cystic fibrosis, if the required dose of pancreatin is exceeded (more than 10,000 EUR F lipase units per 1 kg of body weight), it is rarely possible to develop strictures (fibrous colonopathy) in the ileocecal region and in the ascending colon.

Other: hyperuricemia, hyperuricosuria, folate deficiency.

Interaction

With long-term use of pancreatin in high doses, the absorption of iron supplements (clinically insignificant) and folic acid may be reduced. Periodic monitoring of folate levels and/or folic acid supplementation is recommended.

When used simultaneously with cimetidine and bicarbonates, it is also recommended to periodically monitor folate levels and/or folic acid administration.

Pancreatin may reduce the effectiveness of acarbose and miglitol. The acid-resistant shell of Panzinorm 10000 pellets dissolves in the duodenum. When the pH value in the duodenum is low, pancreatin is not released. The simultaneous use of H2-histamine receptor blockers (cimetidine), bicarbonates, proton pump inhibitors can lead to an increase in the effectiveness of pancreatin, which allows reducing the dose of Panzinorm 10000.

Overdose

Symptoms: nausea, vomiting, diarrhea, hyperuricosuria, hyperuricemia, perianal irritation; Fibrous colonopathy rarely develops (with cystic fibrosis).

Treatment: drug withdrawal, hydration, symptomatic therapy.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

3 years

Manufacturer

KRKA dd Novo Mesto, Slovenia